HLB Acquires Non-Clinical Contract Research Organization Notus for 56.2 Billion KRW
[Asia Economy Reporter Oh Hyung-gil] HL Biopharma announced on the 27th that it will acquire Notus, a contract research organization (CRO) specializing in non-clinical trials such as animal testing.
HL Biopharma will acquire 1,405,648 shares of Notus for 56.2 billion KRW, securing an 18.37% stake and becoming the largest shareholder.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
HL Biopharma stated that it decided to acquire Notus to enter new business areas and maximize synergy with its existing businesses.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
